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Macrophages reside in tissues infiltrated by chronic lymphocytic leukemia B cells and the extent of infiltration is
associated with adverse prognostic factors. We studied blood monocyte population by flow cytometry and whole-
genome microarrays. A mixed lymphocyte reaction was performed to evaluate proliferation of T cells in contact
with monocytes from patients and normal donors. Migration and gene modulation in normal monocytes cultured
with CLL cells were also evaluated. The absolute number of monocytes increased in chronic lymphocytic
leukemia patients compared to the number in normal controls (792±86 cells/mL versus 485±46 cells/mL, P=0.003).
Higher numbers of non-classical CD14+CD16++ and Tie-2-expressing monocytes were also detected in patients.
Furthermore, we performed a gene expression analysis of monocytes in chronic lymphocytic leukemia patients,
showing up-regulation of RAP1GAP and down-regulation of tubulins and CDC42EP3, which would be expected
to result in impairment of phagocytosis. We also detected gene alterations such as down-regulation of PTGR2, a
reductase able to inactivate prostaglandin E2, indicating immunosuppressive activity. Accordingly, the prolifera-
tion of T cells in contact with monocytes from patients was inhibited compared to that of cells in contact with
monocytes from normal controls. Finally, normal monocytes in vitro increased migration and up-regulated CD16,
RAP1GAP, IL-10, IL-8, MMP9 and down-regulated PTGR2 in response to leukemic cells or conditioned media. In
conclusion, altered composition and deregulation of genes involved in phagocytosis and inflammation were found
in blood monocytes obtained from chronic lymphocytic leukemia patients, suggesting that leukemia-mediated
“education” of immune elements may also include the establishment of a skewed phenotype in the
monocyte/macrophage population. 
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ABSTRACT
Introduction 
Tumor-associated macrophages (TAM) play an important
role in tumor cell invasion, proliferation and survival. TAM
have a phenotype and functions more similar to alternatively
activated (M2) macrophages, characterized by the IL-10highIL-
12low profile, poor antigen-presenting capacity, immunosup-
pressive effects and pro-angiogenic properties.1 An increase
in the number of TAM has been associated with shortened
survival and drug-resistance in patients with hematologic
malignancies such as classic Hodgkin's lymphoma, follicular
lymphoma, diffuse large B-cell lymphoma, and multiple
myeloma.2-5 Macrophages are also involved in the ingestion
of rituximab-opsonized cells via the Fcγ receptor and may
have a role in rituximab resistance.6
TAM derive from monocytic precursors circulating in the
blood and are recruited into the tumor tissues by chemoat-
tractants. Monocytes can be divided into three subsets: the
largest population of circulating human monocytes (≈90%),
with high CD14 but no CD16 expression (CD14++CD16–),
are called classical monocytes, whereas the minor popula-
tion is subdivided into the intermediate subset, with low
CD16 and high CD14 (CD14++CD16+), and the non-classical
subset, with high CD16 and lower CD14 expression
(CD14+CD16++).7,8 Moreover, among circulating monocytes,
those expressing the angiopoietin receptor Tie2 (Tie-2-
expressing monocytes, TEM) are characterized by tumor-
promoting properties.9,10
Chronic lymphocytic leukemia (CLL) B cells show pro-
longed survival in vivo and therefore accumulate in peripheral
blood, bone marrow and lymphoid organs of patients. In vitro
CLL cell survival was extended in co-cultures with several
types of cells such as mesenchymal stromal cells, follicular
dendritic cells, endothelial cells and monocytoid cells
(defined as nurse-like cells, NLC).11 The amount of NLC in
CLL-infiltrated bone marrow was reported to be closely
associated with adverse prognostic factors.12
Here, we evaluated the monocytic population in peripher-
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In addition, circulating TEM were measured and com-
pared. We also investigated the ability of leukemic cells
to influence the migration and gene expression profile of
monocytes.
Design and Methods
Further details are provided in the Online Supplementary Design
and Methods.
Patients 
After obtaining informed consent in accordance with the
Declaration of Helsinki with a protocol approved by the local
Institutional Review Board, blood samples were collected from 31
untreated CLL patients fulfilling standard criteria13 and 13 healthy
donors (controls).
Flow cytometry
Peripheral blood mononuclear cells (PBMC) from 26 patients
and 13 age- and gender-matched healthy controls were stained
with anti-CD14 FITC, anti-CD16 APC-Alexa750 (Becton
Dickinson, San José, CA, USA) and anti-TIE-2 PE (R&D Systems,
Minneapolis, MN, USA). Monocytes were divided into classical
(CD14++CD16–), intermediate (CD14++CD16+) and non-classical
(CD14+CD16++) subsets. The percentages of Tie2+ cells among
CD14+ monocytes (TEM) were determined by gating on the
DUMP– channel, as defined in theOnline Supplementary Design and
Methods.
Gene expression analysis
Large-scale gene expression profiling was performed by
hybridizing RNA from highly purified CD14+ monocytes, isolated
from five CLL patients and five healthy controls, on a 4X44K
Whole Human Genome Microarray (Agilent Technologies, Palo
Alto, CA, USA) as previously described.14 The data have been
deposited in the NCBI Gene Expression Omnibus (GEO,
http://www.ncbi.nlm.nih.gov/geo/, GSE35179). Expression of the
RAP1GAP, ARHGEF12, PTGR2 and PLA2G4A genes was meas-
ured by Real-Time Ready Custom Panel 96 and LightCycler 480
Probes Master (Roche Applied Science, Penzberg, Germany). IL-6,
IL-10, IL-8, VEGF and MMP9 were amplified by LightCycler 480
SYBR Green I Master (Roche).
Culture condition of monocytes and nurse-like cells
CD14+ monocytes from healthy donors were cultured in
IMDM supplemented with 2% fetal bovine serum and 2 mM L-
glutamine. Adherent monocytes were exposed to conditioned
media derived from CLL cells (CM CLL, dilution 1:2 with fresh
medium) or to direct contact with CLL cells or normal B cells
(ratio 1:2). Lastly, NLC were obtained from five CLL patients, as
previously described.15
Functional assays
Migration assays were performed on monocytes in 24-well
plates containing 5-mm pore size PET inserts (Millipore, Billerica,
MA, USA). The migratory cells labeled with 8 mM calcein-AM
(Sigma-Aldrich, St. Luis, MO, USA) were quantified by the fluores-
cence plate reader Infinite200 (Tecan, Männedorf, Switzerland). To
evaluate T-cell proliferation, we isolated CD3+ cells from PBMC of
three CLL patients and five healthy donors using the Pan-T cell iso-
lation kit (Miltenyi Biotec, Bergisch Gladbach, Germany).
Autologous and allogeneic mixed reactions were performed by
culturing T cells with adherent monocytes obtained from CLL
patients or normal controls for 5 days. Cell proliferation was mon-
itored using the MTT assay (Trevigen, Gaithersburg, MD, USA) or
CFSE dilution assay (eBioscience, S Diego, CA, USA).
Solid-phase enzyme-linked immunosorbent assays 
The levels of PGE2 (as 13, 14-dihydro-15-keto PGE2), Ang2,
IL-6, IL-10, IL-8, VEGF and MMP9 proteins were determined by
Quantikine ELISA assays (R&D Systems).
Immunohistochemistry and confocal microscopy
For immunohistochemical analysis, sections from lymph node
samples of CLL patients were stained with goat anti-human Tie2
(R&D System) or mouse anti-human CD68 (Novocastra, Leica
Microsystems, Wetzlar, Germany) as previously reported.16 For con-
focal microscopy, cover slips were incubated with anti-Tie2 mono-
clonal antibody, followed by Alexa-488 conjugated secondary anti-
body. Cells were counterstained with Alexa 568–conjugated phal-
loydin (Invitrogen, Portland, OR, USA) as described elsewhere.17
Results
Blood monocyte subsets in chronic lymphocytic
leukemia
We stained PBMC obtained from 26 untreated CLL
patients and 13 healthy donors with anti-CD14 and anti-
CD16 monoclonal antibodies and analyzed cells by poly-
chromatic flow cytometry. The clinical and biological char-
acteristics of CLL patients are presented in Online
Supplementary Table S1. The blood monocyte population
was subdivided on the basis of the expression of CD14, the
lipopolysaccharide receptor broadly expressed by human
monocytes, and CD16, an Fcγ receptor III, into three sub-
sets: classical monocytes (CD14++,CD16–), non-classical
monocytes (CD14+,CD16++) and intermediate monocytes
(CD14++, CD16+) (Figure 1A). As expected, the major
monocytic subset was represented by classical monocytes,
accounting for 66.4%±5.5% and 72.7%±2.1% of total
monocytes in normal controls and CLL patients, respec-
tively; intermediate monocytes accounted for 26.6±5.4%
and 16.9±1.99%, respectively. The non-classical
CD14+CD16++ monocytic subpopulation was significantly
larger in CLL patients than in normal controls (10.4±1.1%
versus 7.0±1.1%, P=0.04) (Figure 1B). 
We then evaluated whether differential representation
of blood monocyte subsets could be detected between
CLL patients with distinct clinical, hematologic and bio-
logical features at the time of blood sample collection.
No significant differences in monocyte subpopulations
were observed among CLL prognostic subsets defined by
age, gender, Binet stage, white blood cell count, IGHV
mutational status, CD38 and ZAP70 expression. The
non-classical monocyte subset was slightly larger in CLL
patients defined, according to fluorescence in situ
hybridization (FISH) abnormalities, as high risk com-
pared to those at low risk (13.6±2.5% versus 8.5±1.0%,
P=0.038) (Figure 1C).
In order to evaluate whether CLL patients had an
increase of CD14+CD16++ cells, or only a shift in the distri-
bution of specific monocyte subsets, we considered the
absolute number of monocytes. CLL patients had a higher
absolute number of monocytes compared to normal con-
trols (792±86 cells/mL versus 485±46 cells/mL, P=0.003) as
well as higher numbers of classical (568±55/mL versus
313±35/mL, P=0.001) and non-classical monocytes
R. Maffei et al.
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(79±9/mL versus 33±4/mL, P=0.001). In addition, the analysis
of absolute numbers of monocytes confirmed the increase
of non-classical monocytes in the CLL subset carrying
high-risk FISH abnormalities (107±13/mL in high risk versus
65±11/mL in low risk, P=0.023).
Tie2 expression in peripheral blood of patients 
with chronic lymphocytic leukemia
CLL cells were reported to secrete angiopoietin-2 (Ang2)
protein, an agonist/antagonist of the Tie2 receptor, and
higher levels of Ang2 were detected in CLL patients with
adverse clinical outcomes.14,18 We, therefore, evaluated in
our cohort the extent of a small subpopulation of circulat-
ing monocytes able to express Tie2 receptor (TEM) and
showing tumor-promoting properties.9 We stained PBMC
from CLL patients and healthy donors with anti-human
Tie2 and CD14 monoclonal antibodies (Figure 2A). TEM
accounted for 19.6±6.2% and 24.5±4.8% of total mono-
cytes in controls and CLL patients, respectively. Dividing
monocytes into subsets, we found that the majority of
TEM were within the intermediate subset accounting for
31.7±4.9% in CLL, whereas there were fewer TEM present
in the classical (23.8±4.8%) or non-classical (15.1±3.7%)
monocyte subsets. No differences in TEM distribution
among monocyte subsets were detected between CLL and
normal controls. 
Considering the absolute number of circulating TEM,
CLL patients had 84.5 TEM/mL compared to 39.9/mL in
normal controls (P=0.02) (Figure 2B). CLL patients with
adverse FISH aberrations had more TEM than patients
with low-risk FISH lesions (157.9±50.2/mL versus
57.1±17.9/mL, P=0.04). The mean number of TEM in CLL
patients harboring the 17p deletion was 253.5/mL com-
pared to 62.9/mL in patients without the deletion (P=0.01).
No significant differences were observed among other CLL
prognostic subsets defined by age, gender, Binet stage,
white blood cell count, IGHV mutational status, CD38 or
ZAP70 expression.
It was recently demonstrated that Ang2 has a role in reg-
ulating the tumor-promoting functions and migration of
TEM.9,10 We investigated the association between Ang2
plasma levels and TEM number in peripheral blood. Ang2
levels were detected in plasma samples collected at the
time of flow cytometric analyses and ranged from 1170
pg/mL to 4052 pg/mL. A significant positive correlation
was found between Ang2 plasma levels and number of cir-
culating TEM (Spearman’s rho=0.42, P=0.032) (Figure 2C). 
Immunohistochemical analysis for the markers CD68
Altered properties of monocytes in CLL
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Figure 1. Distribution of monocyte subsets in peripheral blood of CLL patients and normal controls. (A) Fresh peripheral blood samples were
collected from 26 untreated CLL patients and 13 normal controls. Mononuclear cells were stained with anti-CD14, anti-CD16 monoclonal
antibodies and analyzed by polychromatic flow cytometry. Monocytes were defined as CD14+ and then subdivided in classical monocytes
(CD14++CD16-), non-classical monocytes (CD14+CD16++) and intermediate monocytes (CD14++CD16+) as indicated. (B) Histograms represent
the percentage of classical, intermediate and non-classical monocytes in CLL patients and normal controls. A shift from intermediate (down-
modulated) towards non-classical monocytes (increased) is present in CLL compared to normal controls (*P<0.05, Mann-Whitney non-para-
metric test). (C) When CLL patients were divided into two prognostic subsets on the basis of genomic aberrations detected by FISH analysis
(low risk, no abnormalities or deletion 13q, n=16; high risk= deletions 11q, 17p or trisomy 12, n=7), the unfavorable prognostic subgroup
had an increased percentage of non-classical monocytes (*P<0.05, Mann-Whitney non-parametric test). Data are presented as mean ± stan-
dard error of mean.
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and Tie2 performed on serial lymph node sections con-
firmed that a fraction of NLC intermingling with CLL cells
expressed Tie2 (Figure 3A). These Tie2+ NLC had a pre-
dominantly peri-vascular distribution (Figure 3A).
Concordantly, we found that a subset of adherent NLC
generated in vitro from circulating monocytes of five CLL
patients expressed Tie2 receptor (Figure 3B).
Gene-expression profiling of chronic lymphocytic
leukemia monocytes
Blood monocytes were isolated from five healthy donors
and five previously untreated CLL patients. The clinical
and biological characteristics of the CLL patients are
shown in Online Supplementary Table S2. Gene expression
profiles of the monocyte population were obtained and
analyzed using unsupervised and supervised learning.
Although analyzed cells were not part of the malignant
clone, in unsupervised hierarchical clustering analysis, the
gene expression profiles of normal monocytes were clearly
distinguishable from those of monocytes obtained from
CLL patients. Supervised analysis identified 65 genes sig-
nificantly up-regulated and 48 genes down-regulated in
CLL monocytes compared with monocytes from normal
controls [fold-change (FC) ≥2, P<0.05] (Figure 4A and
Online Supplementary Table S3). Classifying differentially
expressed genes into cellular pathways, we found that up-
regulated genes were involved in the Wnt signaling path-
way, apoptosis, VEGF signaling pathway, and angiogene-
sis, while down-regulated ones were involved in cytoskele-
tal regulation, oxidative stress response and inflammation
signaling. In particular, in monocytes from CLL patients we
found a 6.5-fold up-regulation of RAP1GAP, able to
enhance the intrinsic GTPase activity of RAP1 to
hydrolyze the bound GTP to GDP and inhibit its down-
stream function. RAP1 GTPase has been reported to be
involved in both Fcγ-receptor and complement-receptor
phagocytosis.19 Conversely, we found a 12- and 3-fold
down-regulation of tubulins TUBB3 and TUBB2 as well as
a 2-fold decrement of CDC42EP3, a Rho GTPase effector
protein involved in actin assembly at nascent phagosomes
and internalization of IgG-opsonized particles.20
Functionally, these modifications would be expected to
result in impaired phagocytosis. 
Furthermore, there was a 3.8-fold down-regulation of
the chemokine (C-C motif) ligand 5 (CCL5) involved in M1
polarization and inflammation response. CLL monocytes
up-regulated the leukemia-associated Rho guanine
nucleotide exchange factor 12 (ARHGEF12/LARG)
(FC=2.61) and the lysophosphatidic acid receptor 6
(LPAR6/P2Y5) (FC=3.95), able to activate RhoA GTPase
involved in cell migration and Raf/ERK signaling.21,22
Among up-regulated genes in CLL-derived monocytes, we
also found Toll-like receptor 4 (TLR4) as well as Lipin-2
(LIP2) and -3 (LIP3), two phosphatidic acid (PA) phos-
phatases (PAP). Lipins hydrolyze PA to yield diacylglycerol
(DAG), which activates cytosolic group IVA phospholipase
R. Maffei et al.
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Figure 2. Tie2-expressing monocytes (TEM) in CLL patients
and normal controls. (A) Flow cytometric analysis shows the
percentage of Tie2+ cells among CD14+ monocytes, gated on
the DUMP– channel. (B) Histograms represent mean ± SEM of
TEM count/mL in CLL patients (n=26) and healthy age-
matched controls (n=13) and also within CLL patients divided
according to FISH abnormalities. CLL patients had higher num-
bers of TEM compared to normal controls. Moreover, CLL
patients harboring high-risk FISH abnormalities, in particular
deletion 17p, had higher numbers of TEM in peripheral blood.
(*P<0.05, Mann-Whitney test). (C) TEM count/mL correlates
positively with Angiopoietin-2 (Ang2) plasma levels
(Rho=0.42, P=0.032, Spearman’s non-parametric test).
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A2 (PLA2G4A). PLA2G4A was also found to be 4-fold up-
regulated in CLL monocytes compared to normal mono-
cytes. Functionally, these modifications would be expected
to result in mobilization of free arachidonic acid, the pre-
cursor of inflammatory mediators, eicosanoids.23,24 Finally,
we also found down-regulation of PTGR2 (FC=-3.2),
involved in inactivation of PGE2 as well as reduced expres-
sion of dual specificity phosphatase 3 (DUSP3/VHR) (FC=-
2.0) and cyclin A1 (CCNA1) (FC=-6.2), indicating a reduc-
tion in cycling monocytes (Online Supplementary Table
S3).25,26
We validated the up-regulation of RAP1GAP, ARHGEF12
and PLA2G4A and the down-regulation of PTGR2 by RT-
PCR in monocytes obtained from 12 CLL patients and 13
healthy donors (Figure 4B). Furthermore, we quantified
PGE2 metabolites in conditioned media (CM) collected
from CLL-derived (n=6) and normal (n=8) monocytes after
24 h of culture and in plasma samples from CLL patients
(n=16) and healthy donors (n=8). The levels of PGE2
metabolites were lower in samples from CLL patients than
in those from normal controls (CM, 18±5 versus 41±13
pg/mL; plasma, 144±15 versus 333±143 pg/mL, P<0.05,
Online Supplementary Figure S1).
Chronic lymphocytic leukemia-derived monocytes 
suppress T-cell proliferation
The results of gene expression profiling analysis suggest
that monocytes in CLL patients may have immunosup-
pressive properties that are absent or less marked in normal
monocytes. We, therefore, compared the effect of CLL-
derived monocytes and normal monocytes on proliferation
of autologous T cells. We found that autologous T cells
proliferated less when co-cultured with monocytes from
CLL patients than with monocytes from healthy donors
(n=3 for both, P<0.05, Online Supplementary Figure S2). A
30% reduction in T-cell proliferation was detected in CLL
by a MTT assay, in which metabolically active cells con-
vert MTT into formazan, and confirmed by CFSE dilution
assays. To exclude that the immunosuppression was due
to impairment of CLL-derived T lymphocytes, we also per-
formed an allogeneic lymphocyte reaction. Normal T cells
showed reduced proliferation when cultured on mono-
cytes collected from  CLL patients compared to monocytes
from healthy donors (n=3 for both, P<0.05, Online
Supplementary Figure S2).
Chronic lymphocytic leukemia cells increase CD16 and
RAP1GAP, but decrease PTGR2 expression on monocytes 
To determine whether tumor-derived factors may cause
the observed increase in CD16 and RAPGAP1 expression
and the decrease of PTGR2, monocytes from healthy
donors were cultured with CLL-derived conditioned media
(CM CLL) or in direct contact with CLL cells or normal B
cells. In addition, we evaluated the expression of cytokines
involved in inflammation (IL-6 and IL-10), angiogenesis (IL-
8 and VEGF) and invasiveness (MMP9). Compared to
supernatants from control cells, supernatants from CLL
cells induced a slight increase in CD16 expression on nor-
mal monocytes, as measured by flow cytometry (n=5, 24
h, %CD16+CD14+, 3.3±1.0% in culture controls versus
5.3±1.2% in CM-treated monocytes, P=0.043). As shown
in Figure 5A-B, when monocytes were cultured in contact
Altered properties of monocytes in CLL
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Figure 3. Tie2 staining on nurse-like cells (NLC). (A)
Tie-2 expressing NLC (red signal) populate lymph
node CLL infiltrates. Immunohistochemistry, Strept-
ABC method, original magnifications x200 and
x400. (B) Representative images of NLC cultures
(n=5) showing intense surface staining for the Tie2
receptor. Live CLL lymphocytes are counterstained
using phalloidin.
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with CLL cells, we detected a greater increase in CD16
expression (32.3±5.7%) than in the baseline condition
(18.0±1.6%) or than when the monocytes were treated
with normal B cells (19.3±4.0%) (n=8, P=0.012).
Furthermore, we found that CLL-derived soluble factors
were able to induce up-regulation of RAP1GAP (n=7,
P=0.018) and down-regulation of PTGR2 (n=8, P=0.012) on
normal monocytes (Figure 5C). Normal monocytes also had
up-regulated IL-10, IL-8 and MMP9 expression in response
to CM CLL (all P<0.05) (Figure 5D). No significant varia-
tions were found compared to unstimulated controls for IL-
6 and VEGF expression levels. Moreover, we collected
supernatants from monocyte cultures and the release of
cytokines was measured by ELISA. CLL stimulation
induced normal monocytes to release increased levels of IL-
6 and IL-10 (from 7.9 to 27.3 pg/mL for IL-6 and from 0.39
to 1.43 pg/mL for IL-10, P=0.043 both) (data not shown).
Release of VEGF was unaffected by stimulation. Lastly, we
evaluated whether CLL may stimulate migration of mono-
cytes. Purified CD14+ monocytes were induced to migrate
through a 5 mm-pore size PET membrane for 2 h. We found
that CM CLL increased the migration of monocytes (P<0.05
versus control medium) (Figure 5E).
Discussion
The purpose of our study was to improve knowledge
about in vivo functional and phenotypic deregulation of
monocytes in CLL patients. We found that CLL patients
had a higher absolute number of monocytes compared to
normal controls. In addition, we detected a significant
increase in non-classical monocytes, characterized by a
low level of CD14 together with high CD16
(CD14+CD16++). This modification seems to be more
prominent in CLL cases with adverse genomic aberrations.
However, prospective studies on larger series are necessary
to confirm this observation and to evaluate the association
with other established prognostic factors and clinical
behavior. Of note, we demonstrated that CLL cell contact
in vitro can induce the up-regulation of CD16 expression on
normal monocytes compared to the baseline condition or
to contact with normal B cells. Non-classical monocytes
exhibit patrolling behavior in vivo, are weak phagocytes, do
not produce reactive oxygen species or cytokines in
response to cell-surface Toll-like receptors and react strong-
ly to nucleic acid and viruses, but poorly to lipopolysaccha-
ride.27 In healthy individuals, non-classical monocytes have
a gene expression profile closely related to that of interme-
diate monocytes, but with higher expression of several
genes involved in cytoskeletal rearrangement.7 Moreover,
the number of CD16+ monocytes is increased in patients
with solid tumors and correlates with poor prognosis and
a higher density of TAM.28,29 This subpopulation may rep-
resent more mature monocytes able to adhere to vascular
endothelium and migrate into tumor-involved areas. 
The full spectrum of monocyte functions, and in partic-
ular the specific functions of different monocyte subsets, is
not completely known but comprises anti-inflammatory
properties, tissue repair and angiogenesis. Monocytes form
R. Maffei et al.
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Figure 4. Gene expression profiles of CLL-derived monocytes. (A) Heat map depicts differentially expressed genes between CLL-derived
monocytes and normal monocytes. The data are represented in a grid format in which each column represents a case and each row a single
gene. Normalized intensity signals are depicted in the pseudo color scale as indicated. (B) Histograms represent the mRNA relative quantity
of RAP1GAP, ARHGEF12, PLA2G4A and PTGR2 evaluated by RT-PCR in monocytes obtained from 12 CLL patients and 13 healthy donors.
(*P<0.05, Mann-Whitney test). 
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a heterogeneous population of cells and include TEM,30
which account for 2% to 7% of blood mononuclear cells in
healthy donors. In human cancer patients, TEM were
observed in the blood and, intriguingly, within tumors, but
hardly detected in non-neoplastic tissues.30 We found
increased numbers of TEM in the peripheral blood of CLL
patients and in particular in cases with high-risk genomic
aberrations. Moreover, higher numbers of circulating TEM
were present in CLL characterized by increased plasma lev-
els of Tie2 agonist/antagonist Ang2. CLL cells are able to
secrete Ang2 in infiltrated tissues and higher plasma Ang2
levels are present in CLL patients with adverse clinical out-
come and with increased tissue vascularization.18 Here, we
first found Tie2+ NLC in CLL-infiltrated lymph nodes,
mainly in a peri-vascular distribution. We argue that the
production of Ang2 by leukemic cells in infiltrated-tissue
may mediate not only a pro-angiogenic effect but also the
recruitment into tissue of the TEM subpopulation. TEM
have a profound pro-angiogenic activity, a tumor-promot-
ing M2-like phenotype, suppress T-cell activation and pro-
mote regulatory T-cell expansion via an IL-10-dependent
mechanism.9 Our results indicate a possible role of this sub-
set of monocytes/macrophages in CLL-mediated mecha-
nisms of angiogenesis and immunosuppression. 
Overall, the increased frequencies of CD14+CD16++ and
Tie2-expressing monocytes are additional abnormalities of
circulating monocyte populations in CLL patients besides
the higher number of CD14+CD16–HLA-DRlow/neg immuno-
suppressive monocytes recently reported by Gustafson et
al.31 These alterations seem to be associated with more
aggressive disease. 
Microarray-gene expression profiling is a useful tool for
unraveling the complexity of altered molecular mecha-
nisms in tumor cells and also in non-malignant compo-
nents of cancer-bearing patients. Analysis of the differen-
tially expressed genes in monocytes from CLL patients
compared to normal controls demonstrated a number of
abnormalities in specific pathways. The most up-regulated
gene in NLC is that encoding the GTPase-activating pro-
tein RAP1GAP, able to enhance the intrinsic GTPase activ-
ity of RAP1 to hydrolyze the bound GTP to GDP and as a
consequence inhibit RAP1 downstream functions. The
major biological functions of RAP1 are Ras-mediated ERK
activation and integrin-dependent cellular functions such
as immunological synapse formation, cell adhesion,
macrophage phagocytosis and chemokine-induced migra-
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Figure 5. In vitro CLL-induced modifications of the monocytic population. CD14+ monocytes collected from healthy donors were cultured in
the presence of CLL-derived conditioned media (CM CLL) or in direct contact with CLL cells or normal B cells. (A) Histograms represent the
percentage of CD16+ cells in the monocytic population collected from healthy donors (n=8) measured by flow cytometry at baseline and
after 24 h-culture with normal B cells or with CLL cells. Data are reported as mean±SEM of three independent experiments (*P=0.012,
Wilcoxon’s test). (B) Counter plots of a representative sample showing an increase of CD16+ cells among CD14+ monocytes after CLL contact.
(C-D) mRNA levels were measured by RT-PCR on normal monocytes (n=8) collected after 24 h of treatment with CM CLL and represented
as fold change compared to control medium. CLL-derived soluble factors up-regulate the expression of RAP1GAP, IL-10, IL-8 and MMP9,
whereas they down-regulate PTGR2. All *P<0.05 compared to untreated controls (Wilcoxon’s test). (E) CM-CLL stimulates migration of nor-
mal monocytes. Monocytes were induced to migrate through a 5 mm-pore size PET membrane for 2 h in response to Iscove's modified
Dulbecco's medium (IMDM) (negative control) or 10% fetal bovine serum (FBS) (positive control), and with addition of CM-CLL. Histograms
represent mean±SEM of three independent experiments.  Data are normalized on IMDM controls and represented as fold change. *P<0.05
compared to IMDM control (Wilcoxon’s test). 
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tion of leukocytes. In particular, RAP1 activation is required
for both Fcγ receptor-dependent and b2-integrin-mediated
phagocytosis.19 Inhibition of RAP1 activity by RAP1GAP
expression was reported to induce severe impairment of
the ability of macrophages to ingest opsonized particles.
This abnormality, together with the down-regulation of
tubulins and CDC42EP3, a CDC42 Rho GTPase effector
protein, would be expected to result in impairment in
cytoskeleton rearrangement, cell spreading and phagocyto-
sis. Immunomodulatory drugs rapidly regulate cytoskele-
ton reorganization in monocytes and T cells through selec-
tive activation of Rho family GTPases, inducing increase in
F-actin formation, microtubule stabilization and synapse
formation.32 In the light of our findings, the normalization
of leukemia-derived impairment of actin cytoskeleton in
both T cells and monocytes by immunomodulatory drugs
could be a key mechanism of immune activation described
in CLL patients treated with immunomodulatory drugs.
Furthermore, impairment of IgG-mediated phagocytosis
may be considered a potential mechanism of rituximab-
resistance in CLL patients.6 Further studies are necessary to
unravel these issues. 
Our gene expression analysis of CLL monocytes
showed up-regulation of TLR4 and protein kinase C-ε
(PRKCE) as well as up-regulation of two lipins (LPIN2 and
LPIN3), metabolic enzymes that possess PAP activity,
hydrolyzing PA to yield DAG. DAG regulates the activa-
tion of the cytosolic PLA2G4A, which also showed a 4-
fold up-regulation in NLC. PLA2G4A induces the mobi-
lization of free arachidonic acid to produce eicosanoids.33
These abnormalities could imply activation of NFκB sig-
naling pathways and production of pro-inflammatory
mediators. On the other hand, TLR4 activation in TAM
was reported to enhance tumor growth and to mediate
production of angiogenic factors.34 Moreover, PLA2G4A
was up-regulated during M2 polarization of macrophages
and contributed to cytotoxic T-cell immunosuppression.35
A possible explanation could be the generation of specific
immunosuppressive eicosanoids such as PGE2.36 In agree-
ment with this hypothesis, we also found down-regula-
tion of PTGR2, which catalyzes the reaction for inactivat-
ing PGE2, with a consequent decreased level of PGE2
metabolites secreted by CLL-derived monocytes and also
in CLL plasma samples. PGE2 suppresses multiple
immune functions; for example, it inhibits proliferation
and stimulation of T cells and represses macrophage acti-
vation, it promotes IL-10 and reduces IL-12 expression, it
inhibits the maturation of dendritic cells, induces Th2
responses, and also exerts a suppressive effect on B-cell
function.25 The aberration identified by gene expression
profiling would be expected to cause increased accumula-
tion, compared to the normal condition, of PGE2 due to
reduced activity of degradation and inactivation in NLC.
Together with leukemic production of PGE2 by constitu-
tive expression of cyclo-oxygenase-2,37 this abnormality
could contribute to immunosuppression in CLL patients.
We demonstrated that monocytes collected from CLL
patients had immunosuppressive properties inducing the
inhibition of T-cell proliferation. Further studies are neces-
sary to unravel the functional role of increased PGE2 pro-
duction in CLL monocytes.  
Lastly, we found that CLL cells were able to attract
monocytes and to induce the up-regulation of some tumor-
promoting factors. In particular, RAP1GAP up-regulation
and PTGR2 down-regulation were induced in normal
monocytes when cultured with CLL-derived CM.
Moreover, CLL stimulation of normal monocytes also
implied the up-regulation of IL-10, a Th2-derived cytokine
able to inhibit the inflammatory response, the up-regula-
tion of IL-8, a pro-angiogenic CXC chemokine, and the
increase of MMP9, a proteolytic proenzyme involved in
degradation of the extracellular matrix.25
CLL patients have leukemic cells expressing high levels
of immune-suppressing factors, low levels of adhesion and
co-stimulatory molecules, lower numbers of natural killer
cells, and deregulated T cells with an impairment of
immunological synapse formation. The alterations
described in our study further contribute to characterizing
the complexity of factors potentially involved in the
acquired immune deficiency of CLL patients. In conclu-
sion, we detected altered composition and deregulation of
genes involved in phagocytosis and inflammation in blood
monocytes obtained from CLL patients, suggesting that
CLL-mediated “education” of immune elements may also
include the establishment of a skewed phenotype in the
monocyte/macrophage population.
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